MX2020003133A - Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico. - Google Patents

Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico.

Info

Publication number
MX2020003133A
MX2020003133A MX2020003133A MX2020003133A MX2020003133A MX 2020003133 A MX2020003133 A MX 2020003133A MX 2020003133 A MX2020003133 A MX 2020003133A MX 2020003133 A MX2020003133 A MX 2020003133A MX 2020003133 A MX2020003133 A MX 2020003133A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
acetic acid
composition containing
acid compound
specific compound
Prior art date
Application number
MX2020003133A
Other languages
English (en)
Other versions
MX385505B (es
Inventor
Yoko Endo
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of MX2020003133A publication Critical patent/MX2020003133A/es
Publication of MX385505B publication Critical patent/MX385505B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

El propósito de la presente invención es proporcionar una composición farmacéutica que comprende un compuesto específico y exhibe una eficacia de conservación superior, el compuesto específico siendo estable dentro de la composición farmacéutica, y proporcionar métodos para mejorar la estabilidad del compuesto específico dentro de la composición farmacéutica y la eficacia de conservación de la composición farmacéutica. La composición farmacéutica de acuerdo a la presente invención comprende (6-{[4-(pirazol-1-il)bencil](piridin-3-ilsulfonil)aminometil}piri din-2-ilamino)acetato de isopropilo o una sal del mismo, y además comprende ácido edético o una sal del mismo.
MX2020003133A 2014-01-10 2015-01-08 Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico MX385505B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014002810 2014-01-10
PCT/JP2015/050334 WO2015105135A1 (ja) 2014-01-10 2015-01-08 ピリジルアミノ酢酸化合物含有医薬組成物

Publications (2)

Publication Number Publication Date
MX2020003133A true MX2020003133A (es) 2021-08-23
MX385505B MX385505B (es) 2025-03-18

Family

ID=53523960

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016009049A MX2016009049A (es) 2014-01-10 2015-01-08 Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico.
MX2020003133A MX385505B (es) 2014-01-10 2015-01-08 Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016009049A MX2016009049A (es) 2014-01-10 2015-01-08 Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico.

Country Status (19)

Country Link
US (5) US10149908B2 (es)
EP (1) EP3093019B1 (es)
JP (1) JP6441087B2 (es)
KR (1) KR102281620B1 (es)
CN (1) CN105828818B (es)
AU (1) AU2015205179B2 (es)
BR (1) BR112016015909B1 (es)
CA (1) CA2935055C (es)
EA (1) EA031813B1 (es)
ES (1) ES2875307T3 (es)
GE (2) GEAP201914215A (es)
IL (1) IL246655B (es)
MX (2) MX2016009049A (es)
MY (1) MY179951A (es)
PH (1) PH12016501328B1 (es)
SG (1) SG11201605366QA (es)
TW (1) TWI650127B (es)
UA (1) UA121746C2 (es)
WO (1) WO2015105135A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150279T1 (hr) 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
KR101858373B1 (ko) * 2014-01-10 2018-05-15 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
EP3093018B1 (en) 2014-01-10 2018-11-28 Santen Pharmaceutical Co., Ltd Pharmaceutical preparation including pyridylamino acetic acid compound
CA2935055C (en) 2014-01-10 2021-08-24 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition containing pyridylaminoacetic acid compound
US20180200239A1 (en) 2015-07-09 2018-07-19 Santen Pharmaceutical Co., Ltd. Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound
TWI751136B (zh) * 2016-02-22 2022-01-01 日商參天製藥股份有限公司 含多佐胺與溴莫尼定之醫藥組成物
US11433090B2 (en) 2017-06-16 2022-09-06 The Doshisha mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
WO2018230713A1 (ja) 2017-06-16 2018-12-20 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
WO2019065838A1 (ja) 2017-09-29 2019-04-04 参天製薬株式会社 ピリジルアミノ酢酸化合物を含有する医薬
CA3086445A1 (en) 2017-12-21 2019-06-27 Santen Pharmaceutical Co., Ltd. Omidenepag combination
CN111526876A (zh) 2017-12-28 2020-08-11 参天制药株式会社 含有吡啶基氨基乙酸化合物的药物制剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
JP3297969B2 (ja) 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
EP0938896A1 (en) * 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent
BR9906597A (pt) 1998-07-14 2000-07-18 Alcon Lab Inc Produto de prostaglandina
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
US20020009507A1 (en) 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
JP2002356420A (ja) * 2001-03-27 2002-12-13 Santen Pharmaceut Co Ltd 安定な水性液剤
JP5460996B2 (ja) * 2007-10-19 2014-04-02 大正製薬株式会社 眼科用剤
HRP20190509T1 (hr) * 2008-03-12 2019-05-03 Ube Industries, Ltd. Spoj piridilaminooctene kiseline
PT2415763E (pt) * 2009-03-30 2016-03-30 Ube Industries Composição farmacêutica para tratamento ou prevenção do glaucoma
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
TW201309343A (zh) * 2011-02-10 2013-03-01 參天製藥股份有限公司 經改善親水性藥物之藥物移行性之水性組成物
KR20140038404A (ko) 2011-04-12 2014-03-28 가부시키가이샤 아루떼꾸 우에노 수성 안과용 조성물
JP5345743B1 (ja) 2012-02-27 2013-11-20 ロート製薬株式会社 眼科用組成物キット
KR101536885B1 (ko) 2012-03-26 2015-07-14 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 함유 점안액
CN104428911B (zh) 2012-07-09 2018-08-24 夏普株式会社 发光装置以及照明装置
US20140018350A1 (en) 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
CA3099517C (en) * 2012-07-13 2022-04-26 Santen Pharmaceutical Co., Ltd. Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
JP2014019650A (ja) * 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
CA2935055C (en) * 2014-01-10 2021-08-24 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition containing pyridylaminoacetic acid compound
EP3093018B1 (en) 2014-01-10 2018-11-28 Santen Pharmaceutical Co., Ltd Pharmaceutical preparation including pyridylamino acetic acid compound
KR101858373B1 (ko) 2014-01-10 2018-05-15 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물

Also Published As

Publication number Publication date
KR102281620B1 (ko) 2021-07-23
PH12016501328A1 (en) 2017-02-06
CN105828818A (zh) 2016-08-03
NZ722144A (en) 2021-05-28
US20160317664A1 (en) 2016-11-03
AU2015205179B2 (en) 2019-09-19
UA121746C2 (uk) 2020-07-27
CA2935055C (en) 2021-08-24
SG11201605366QA (en) 2016-08-30
EA031813B1 (ru) 2019-02-28
BR112016015909B1 (pt) 2020-09-29
MY179951A (en) 2020-11-19
GEP20196982B (en) 2019-06-25
MX2016009049A (es) 2016-09-09
WO2015105135A1 (ja) 2015-07-16
US10765750B2 (en) 2020-09-08
CA2935055A1 (en) 2015-07-16
CN105828818B (zh) 2020-06-02
AU2015205179A1 (en) 2016-07-28
GEAP201914215A (en) 2019-02-25
IL246655A0 (en) 2016-08-31
US20200353084A1 (en) 2020-11-12
JP6441087B2 (ja) 2018-12-19
EP3093019A4 (en) 2017-07-26
PH12016501328B1 (en) 2020-07-01
EP3093019A1 (en) 2016-11-16
TWI650127B (zh) 2019-02-11
US20200046839A1 (en) 2020-02-13
JP2015147763A (ja) 2015-08-20
EP3093019B1 (en) 2021-05-26
MX385505B (es) 2025-03-18
KR20160099582A (ko) 2016-08-22
US10485872B2 (en) 2019-11-26
TW201609097A (zh) 2016-03-16
IL246655B (en) 2020-05-31
US20190060459A1 (en) 2019-02-28
HK1224190A1 (zh) 2017-08-18
EA201691244A1 (ru) 2016-12-30
US20240024484A1 (en) 2024-01-25
US10149908B2 (en) 2018-12-11
ES2875307T3 (es) 2021-11-10

Similar Documents

Publication Publication Date Title
MX2020003133A (es) Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico.
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
MX2021007432A (es) Compuestos y composiciones para inhibir la actividad de shp2.
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MX2017006366A (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa.
MX2014004725A (es) Formulaciones de etanercept estabilizadas con aminoacidos.
EP4302830A3 (en) Quinazoline derivatives used to treat hiv
CA2983453A1 (en) Naphthyridine compounds as jak kinase inhibitors
MY192824A (en) Compound targeting il-23a and tnf-alpha and uses thereof
EA201691139A1 (ru) Фармацевтическая композиция, содержащая соединение пиридиламиноуксусной кислоты и полиоксиэтиленовое касторовое масло
HK1200812A1 (en) Rod -like hepatitis c virus inhibitors containing the fragement {2- [4- (bi phenyl - 4 - yl) - 1h - imidazo - 2 - yl] pyrrolidine - 1 - carbonlymethyl} amine
WO2013134353A8 (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
MX2016014911A (es) Acidos hidroxamicos heterociclicos como inhibidores de proteina desacetilasa e inhibidores dobles de proteina desacetilasa-proteina cinasa, y metodos de uso de los mismos.
PH12016501462A1 (en) Neprilysin inhibitors
HK1249504A1 (zh) 用作溴结构域抑制剂的吡啶酮二甲酰胺
PH12016501461A1 (en) 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
PH12014501712A1 (en) Novel morpholinyl derivatives useful as mogat-2-inhibitors
SG11201903463PA (en) Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same
PH12017500435A1 (en) A salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
NZ724063A (en) Pyrazine derivatives having pharmaceutical activity
TN2014000307A1 (en) Novel morpholinyl derivatives useful as mogat-2 inhibitors
HK1202529A1 (zh) 非典型性蛋白激酶c的噻吩并嘧啶类抑制剂
HK1231074A1 (en) Neprilysin inhibitors